Novavax | NVAX - Los Gastos Financieros De La Deuda





Los Gastos Financieros De La Deuda Cambio Fecha
Adma Biologics USD 2.1M 474K 2026-03
Agenus USD 16.02M 2.85M 2025-12
AstraZeneca USD 484M 181M 2025-12
BioCryst Pharmaceuticals USD 14.14M 5.53M 2025-12
Cassava Sciences USD 108.37M 396.06M 2026-03
Geron USD 7.15M 150K 2026-03
GlaxoSmithKline GBP 167M 21M 2026-03
MannKind USD 12.43M 1.44M 2026-03
Merck USD 479M 67M 2026-03
Minerva Neurosciences USD 2.31M 60K 2024-06
Moderna USD 11.49B 36B 2026-03
Novartis USD 281M 8M 2025-09
Novavax USD 5.82M 342K 2025-12
Pfizer USD 671M 40M 2026-03
Sanofi EUR 178M 203M 2026-03
Sarepta Therapeutics USD 20.84M 13.28M 2025-12
TG Therapeutics USD 7.67M 1.13M 2026-03